HepaSphere Chemoembolization in Advanced HCC Patients: Safety & Efficacy Registry in China

NCT02743065 · clinicaltrials.gov ↗

UNKNOWN

Status

100

Enrollment

OTHER

Sponsor class

Conditions

Hepatocellular Carcinoma

Interventions

DEVICE: HepaSphere with 50-75mg Doxorubicin

Sponsor

Fifth Affiliated Hospital, Sun Yat-Sen University

Collaborators

[object Object]